Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Perspective Therapeutics (CATX) Stock Price & Analysis
971 Followers
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.21 - $1.90
Previous Close$1.84
Volume2.43M
Average Volume (3M)4.35M
Market Cap
$1.08B
Enterprise Value$1.05B
Total Cash (Recent Filing)$28.32M
Total Debt (Recent Filing)$2.58M
Price to Earnings (P/E)-19.8
Beta0.51
Next Earnings
May 15, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding586,915,977
10 Day Avg. Volume4,720,630
30 Day Avg. Volume4,350,637
Standard Deviation0.46
R-Squared0.03
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)34.28
Price to Sales (P/S)431.11
Price to Cash Flow (P/CF)-33.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue136.85
Enterprise Value/Gross Profit228.38
Enterprise Value/Ebitda-36.57
Forecast
1Y Price Target
$1.78Price Target Upside1.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Perspective Therapeutics News
Ownership Overview
21.09% Insiders
2.74% Mutual Funds
5.25% Other Institutional Investors
70.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $0.20 and its highest was $1.90 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is May 15, 2024 which is in 7 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Mar 28, 2024. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.038 by -$0.022.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.02.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 586,915,950 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.038. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Baker Bros Advisors LP. It holds Perspective Therapeutics’s shares valued at 3M.
---
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.78 (1.71% Upside)
$1.78 (1.71% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 142.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $57.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$1.78
▲(1.71% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+306.43%
reiterated a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +306.43% per trade.
---